CTNI-16. FEASIBILITY PILOT STUDY OF OKN-007 IN COMBINATION WITH ADJUVANT TEMOZOLOMIDE CHEMORADIOTHERAPY IN PATIENTS WITH NEWLY DIAGNOSED GLIOBLASTOMA

BACKGROUND: Temozolomide (TMZ) is the standard of care chemotherapy agent for glioblastoma. Unfortunately, intrinsic or acquired resistance eventually renders TMZ ineffective. The novel anti-cancer agent OKN-007 plus TMZ increased survival in glioma-bearing mice compared to TMZ alone. Furthermore, O...

Täydet tiedot

Tallennettuna:
Bibliografiset tiedot
Julkaisussa:Neuro Oncol
Päätekijät: Battiste, James, Sung, Sarah, Wright, Deborah, Glenn, Chad, Algan, Ozer, Teague, April, Zhao, Yan, Cohoon, Andrew, Kim, Hyun Sook, Towner, Rheal
Aineistotyyppi: Artigo
Kieli:Inglês
Julkaistu: Oxford University Press 2020
Aiheet:
Clinical Trials: Non-Immunologic
Linkit:https://ncbi.nlm.nih.gov/pmc/articles/PMC7650353/
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1093/neuonc/noaa215.183
Tagit: Lisää tagi
Ei tageja, Lisää ensimmäinen tagi!

Samankaltaisia teoksia